Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
REGENXBIO Inc. | Chief Financial Officer | Common Stock | 58.9K | $726K | $12.34 | Sep 16, 2024 | Direct |
Avalo Therapeutics, Inc. | Director | Restricted Stock Units | 9.5K | $4.93K | $0.52 | Aug 13, 2024 | Direct |
REGENXBIO Inc. | Chief Financial Officer | Stock Options (Right to buy) | 289K | Sep 16, 2024 | Direct | ||
Avalo Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 24.6K | Aug 13, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
RGNX | REGENXBIO Inc. | Sep 16, 2024 | 2 | $0 | 4 | Sep 18, 2024 | Chief Financial Officer |
RGNX | REGENXBIO Inc. | Sep 16, 2024 | 0 | $0 | 3 | Sep 18, 2024 | Chief Financial Officer |
AVTX | Avalo Therapeutics, Inc. | Aug 13, 2024 | 2 | $0 | 4 | Aug 14, 2024 | Director |
AVTX | Avalo Therapeutics, Inc. | Dec 20, 2023 | 1 | $0 | 4 | Dec 21, 2023 | Director |
AVTX | Avalo Therapeutics, Inc. | Jun 14, 2022 | 1 | $0 | 4 | Jun 15, 2022 | Director |
AVTX | Avalo Therapeutics, Inc. | Dec 1, 2021 | 1 | $0 | 4 | Dec 3, 2021 | Director |
AVTX | Avalo Therapeutics, Inc. | Dec 1, 2021 | 0 | $0 | 3 | Dec 3, 2021 | Director |